Table e-1. Comparison of three subsets of the study cohort

Characteristic	Invited for the fall 2014 update survey (N=12492)							
	Respondents included in this study (n=6662, 53.3%)	Respondents not included in this study (n=939, 7.5%)	Non-respondents to the survey (n=4891, 39.2%)	P-value				
Female, N (%)	5138 (79.5)	680 (75.7)	2936 (79.3)	0.03				
Caucasian, N (%)	6298 (94.9)	876 (93.8)	4142 (92.8)	< 0.0001				
Age at the time of survey, mean (SD)	58.7 (10.1)	60.7 (10.1)	55.0 (12.2)	< 0.0001				
Employment (prior 6 months), N (%)				0.001*				
Full-time	1471 (27.3)	131 (20.6)	-					
Part-time	678 (12.6)	87 (13.7)	-					
Not employed	3242 (60.1)	419 (65.8)	-					
Income change (prior 6 months (Yes)), N (%)	1033 (15.6)	135 (14.7)	-	0.36*				
Annual income, N (%)				<0.0001*				
≤\$30,000	1384 (26.8)	245 (36.8)	-					
\$30,001 - \$100,000	2658 (51.4)	328 (49.3)	-					
>\$100,000	1129 (21.8)	93 (14.0)	-					
Married (Yes), N (%)	3477 (63.5)	486 (62.5)	2439 (62.3)	0.47				
Age at disease onset, mean (SD)	38.7 (9.7)	38.7 (9.9)	38.1 (10.0)	0.02				
Disease duration (years), mean (SD)	20.0 (9.8)	22.0 (10.7)	-	<0.0001*				
Current MS course, N (%)				<0.0001*				
RRMS	3813 (57.2)	429 (45.7)	-					
PMS	2038 (30.6)	334 (35.6)	-					
Current PDDS, median (interquartile range)	3 (1, 4)	3 (1, 5)	3 (1, 4)	< 0.0001				
Disability benefits (Yes), N (%)	2587 (47.6)	381 (57.0)	· ,	<0.0001*				

^{*}Due to missing values of non-respondents, the comparisons were made only between the respondents included in the study and those not included.

RRMS = relapsing remitting MS, PMS = progressive MS, PDDS = Patient Determined Disease Steps

Table e-2. Characteristics of various subset of the RRMS study cohort*

Characteristic	RRMS respondents who did not take DMTs (N=741)			RRMS respondents who took DMTs (N=3072)			RRMS Respondents who obtained DMTs through insurance by type (N=2241)				
	Personal choice/ Physician recommendation (N=673)	Insurance/ Financial reasons (N=80)	p-value **	Free/discounted drug program (N=818)	Insurance (N=2569)	p- value**	Only private (N=1277)	Only Public (N=361)	Public + Private (N=340)	Public+ (N=165)	p-value
Female, N (%)	577 (85.7)	69 (86.3)	0.94	719 (87.9)	2148 (83.6)	0.004	1097 (85.9)	279 (77.3)	271 (79.7)	137 (83.0)	0.0003
Caucasian, N (%)	639 (95.0)	69 (86.3)	0.004	762 (93.2)	2392 (93.1)	0.62	1211 (94.8)	324 (89.8)	317 (93.2)	149 (90.3)	0.0022
Age at disease onset, mean (SD)	39.4 (9.5)	37.6 (10.4)	0.05	37.6 (9.5)	37.8 (9.4)	0.82	37.2 (8.9)	38.3 (9.8)	40.6 (10.3)	42.4 (10.3)	<0.0001
Age at the time of survey, mean (SD)	59.3 (9.6)	56.4 (8.8)	0.02	53.8 (10.0)	55.1 (9.7)	0.11	52.6 (8.5)	56.1 (10.4)	60.3 (8.4)	63.3 (8.8)	<0.0001
Employment in the prid Full-time	or 6 months, N (%) 160 (30.4)	21 (32.3)		263 (38.2)	879 (40.5)		662 (58.8)	20 (6.8)	20 (7.8)	5 (3.8)	
Part-time	74 (14.1)	15 (23.1)	0.25	103 (15.0)	324 (14.9)	0.005	171 (15.2)	51 (17.2)	30 (11.8)	22 (16.8)	<0.0001
Not employed	292 (55.5)	29 (44.6)		323 (46.9)	969 (44.6)		292 (26.0)	225 (76.0)	205 (80.4)	104 (79.4)	
Income change in the prior 6 months (Yes), N (%)	103 (16.4)	25 (33.8)	0.001	144 (18.8)	467 (19.2)	0.39	266 (21.9)	49 (14.5)	48 (14.8)	27 (17.2)	0.002
Negative insurance change in the prior 12 months (Yes), N (%)	165 (24.5)	44 (55.0)	<0.0001	244 (29.8)	564 (22.0)	<0.0001	293 (22.9)	55 (15.2)	69 (20.3)	24 (14.6)	0.002
Annual income, N (%) ≤\$30,000	138 (26.5)	29 (45.3)	0.0008	176 (26.9)	397 (19.6)	<0.0001	63	163	62	41	<0.0001
\$30,001 - \$100,000	264 (50.8)	32 (50.0)		367 (56.0)	991 (49.0)		(6.3) 481 (48.3)	(56.8) 105 (36.6)	(23.1) 158 (58.7)	(30.6) 65 (48.5)	
>\$100,000	118 (22.7)	3 (4.7)		112 (17.1)	634 (31.4)		452 (45.4)	19 (6.6)	49 (18.2)	28 (20.9)	
Married (yes), N (%)	446 (67.0)	37 (46.3)	0.0008	520 (64.0)	1755 (68.8)	0.009	939 (74.1)	178 (49.7)	247 (73.5)	106 (64.2)	
Disease duration (years), mean (SD)	19.9 (8.9)	18.7 (9.1)	0.64	15.8 (8.1)	17.0 (8.7)	0.08	15.7 (7.6)	18.2 (9.9)	20.4 (9.6)	21.0 (9.8)	<0.0001
Current PDDS, median	2 (1, 4)	3 (1, 4)	0.009	2 (1, 4)	2 (1, 4)	0.2	1 (0, 3)	3 (2, 5)	3 (2, 4)	(9.6) 4 (1, 5)	<0.0001
(interquartile) Disability benefits (yes), N (%)	199 (37.0)	30 (44.8)	0.13	281 (41.0)	781 (36.7)	0.0002	152 (14.2)	224 (75.4)	194 (73.2)	90 (62.9)	<0.0001

^{*} Subsets of the RRMS study cohort were categorized by reasons not taking disease-modifying therapies (DMTs), resources to pay for DMTs, and types of insurances

RRMS = relapsing remitting MS, PMS = progressive MS, PDDS = Patient Determined Disease Steps

^{**}When calculating p values, the overlapping in the two groups was excluded to avoid the underestimate of the difference between the two groups as well as the variance of the two groups.